This talk aims to provide a rapid introduction to the state of the nascent psychedelic sector, fertilising the ground for more substantive discussions on this track. Helped along by data visualisations, Hardman surveys the financial, research and policy contexts in which psychedelic businesses are embedded; and, increasingly, are shaping. The talk finishes by reviewing a number of open questions surrounding the future of the psychedelic sector, from its unfolding clinical evidence base to its commercial viability.